Cargando…

Characterization of the Synergistic Inhibition of I(K(erg)) and I(K(DR)) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor

Ribociclib (RIB, LE011, Kisqali(®)), an orally administered inhibitor of cyclin-dependent kinase-4/6 (CDK-4/6) complex, is clinically effective for the treatment of several malignancies, including advanced breast cancer. However, information regarding the effects of RIB on membrane ion currents is l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Pin-Yen, Chang, Wei-Ting, Wu, Sheng-Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663338/ https://www.ncbi.nlm.nih.gov/pubmed/33138174 http://dx.doi.org/10.3390/ijms21218078

Ejemplares similares

Effective Perturbations by Phenobarbital on I(Na), I(K(erg)), I(K(M)) and I(K(DR)) during Pulse Train Stimulation in Neuroblastoma Neuro-2a Cells
por: Wu, Po-Ming, et al.
Publicado: (2022)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I (K(M)) or I (K(DR)) and in the Stimulation of I (MEP)
por: Chang, Wei-Ting, et al.
Publicado: (2020)

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck
por: van Caloen, Gabrielle, et al.
Publicado: (2021)

The Evidence for Sparsentan-Mediated Inhibition of I(Na) and I(K(erg)): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor
por: Chuang, Tzu-Hsien, et al.
Publicado: (2021)

Bisoprolol, Known to Be a Selective β(1)-Receptor Antagonist, Differentially but Directly Suppresses I(K(M)) and I(K(erg)) in Pituitary Cells and Hippocampal Neurons
por: So, Edmund Cheung, et al.
Publicado: (2019)

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
por: Kim, Sunkyu, et al.
Publicado: (2018)

The Effectiveness of Isoplumbagin and Plumbagin in Regulating Amplitude, Gating Kinetics, and Voltage-Dependent Hysteresis of erg-mediated K(+) Currents
por: Chen, Linyi, et al.
Publicado: (2022)

Effective Perturbations of the Amplitude, Gating, and Hysteresis of I(K(DR)) Caused by PT-2385, an HIF-2α Inhibitor
por: Hsiao, Hung-Tsung, et al.
Publicado: (2021)

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
por: Kim, Sunkyu, et al.
Publicado: (2020)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa, Dumessa, et al.
Publicado: (2017)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
por: Tamura, Kenji, et al.
Publicado: (2016)

Chemical inhibitors of cyclin-dependent kinase (CDKi) improve pancreatic endocrine differentiation of iPS cells
por: Ning, Heming, et al.
Publicado: (2023)

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
por: Jonchere, Barbara, et al.
Publicado: (2023)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
por: Seront, Emmanuel, et al.
Publicado: (2019)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
por: Bahleda, Rastislav, et al.
Publicado: (2017)

Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors
por: Abdalla, Ashraf N., et al.
Publicado: (2020)

A k-nearest neighbor classification of hERG K(+) channel blockers
por: Chavan, Swapnil, et al.
Publicado: (2016)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
por: Łukasik, Paweł, et al.
Publicado: (2021)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K(+) Channel
por: El Harchi, Aziza, et al.
Publicado: (2012)

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2017)

Absence of cyclin-dependent kinase inhibitor p27 or p18 increases efficiency of iPSC generation without induction of iPSC genomic instability
por: Zhan, Zhiyan, et al.
Publicado: (2019)

Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity
por: Fujino, Aiko, et al.
Publicado: (2013)

Cyclin I-like (CCNI2) is a cyclin-dependent kinase 5 (CDK5) activator and is involved in cell cycle regulation
por: Liu, Chengcheng, et al.
Publicado: (2017)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells
por: Strnad, M., et al.
Publicado: (2001)

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
por: Strnad, M., et al.
Publicado: (2001)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ
por: Ahn, Sungjin, et al.
Publicado: (2020)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Saxitoxin Is a Gating Modifier of hERG K(+) Channels
por: Wang, Jixin, et al.
Publicado: (2003)

Up-Regulation of hERG K(+) Channels by B-RAF
por: Pakladok, Tatsiana, et al.
Publicado: (2014)

Erratum: Cyclin I-like (CCNI2) is a cyclin-dependent kinase 5 (CDK5) activator and is involved in cell cycle regulation
por: Liu, Chengcheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gqi0sq6l9dsvrljqktn4fke77a